Mangoceuticals, Inc. Common Stock
Mangoceuticals, Inc. engages in the development, marketing, and sale of various men's wellness products and services through a telemedicine platform in the United States. The company offers erectile dysfunction products under the Mango brand; hair loss products under the Grow brand; hormone balance and therapy products under the Mojo brand; and weight loss products under the Slim brand. It also p… Read more
Mangoceuticals, Inc. Common Stock (MGRX) - Net Assets
Latest net assets as of September 2025: $15.73 Million USD
Based on the latest financial reports, Mangoceuticals, Inc. Common Stock (MGRX) has net assets worth $15.73 Million USD as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($16.53 Million) and total liabilities ($804.27K). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $15.73 Million |
| % of Total Assets | 95.13% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 836.88 |
Mangoceuticals, Inc. Common Stock - Net Assets Trend (2021–2024)
This chart illustrates how Mangoceuticals, Inc. Common Stock's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Mangoceuticals, Inc. Common Stock (2021–2024)
The table below shows the annual net assets of Mangoceuticals, Inc. Common Stock from 2021 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $13.95 Million | +1699.93% |
| 2023-12-31 | $774.75K | +26.18% |
| 2022-12-31 | $614.03K | +3772.43% |
| 2021-12-31 | $-16.72K | -- |
Equity Component Analysis
This analysis shows how different components contribute to Mangoceuticals, Inc. Common Stock's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 2078889400.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $325.00 | 0.00% |
| Other Comprehensive Income | $-9.85K | -0.07% |
| Other Components | $34.76 Million | 249.26% |
| Total Equity | $13.95 Million | 100.00% |
Mangoceuticals, Inc. Common Stock Competitors by Market Cap
The table below lists competitors of Mangoceuticals, Inc. Common Stock ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
RENDER CUBE BSAC ZY -10
F:W63
|
$3.66 Million |
|
Keynote Financial Services Limited
NSE:KEYFINSERV
|
$3.66 Million |
|
Citra Nusantara Gemilang Tbk.
JK:CGAS
|
$3.66 Million |
|
ROCHE HLDG - Dusseldorf Stock Exchang
DU:RHO
|
$3.66 Million |
|
Epsium Enterprise Limited Ordinary Shares
NASDAQ:EPSM
|
$3.65 Million |
|
Yong Concrete PCL
BK:YONG
|
$3.65 Million |
|
Shrinkflex (Thailand) Public Company Limited
BK:SFT
|
$3.65 Million |
|
Fenbo Holdings Limited Ordinary Shares
NASDAQ:FEBO
|
$3.64 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Mangoceuticals, Inc. Common Stock's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 774,754 to 13,946,129, a change of 13,171,375 (1700.1%).
- Net loss of 8,706,000 reduced equity.
- Dividend payments of 802,109 reduced retained earnings.
- New share issuances of 3,978,268 increased equity.
- Other comprehensive income decreased equity by 9,845.
- Other factors increased equity by 18,711,061.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-8.71 Million | -62.43% |
| Dividends Paid | $802.11K | -5.75% |
| Share Issuances | $3.98 Million | +28.53% |
| Other Comprehensive Income | $-9.85K | -0.07% |
| Other Changes | $18.71 Million | +134.17% |
| Total Change | $- | 1700.07% |
Book Value vs Market Value Analysis
This analysis compares Mangoceuticals, Inc. Common Stock's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.06x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2021-12-31 | $-0.02 | $0.40 | x |
| 2022-12-31 | $0.53 | $0.40 | x |
| 2023-12-31 | $0.72 | $0.40 | x |
| 2024-12-31 | $7.05 | $0.40 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Mangoceuticals, Inc. Common Stock utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -62.43%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -1413.60%
- • Asset Turnover: 0.04x
- • Equity Multiplier: 1.10x
- Recent ROE (-62.43%) is above the historical average (-394.23%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2021 | 0.00% | 0.00% | 0.00x | 0.00x | $-16.03K |
| 2022 | -325.40% | -22352.11% | 0.01x | 1.63x | $-2.06 Million |
| 2023 | -1189.08% | -1259.40% | 0.70x | 1.36x | $-9.29 Million |
| 2024 | -62.43% | -1413.60% | 0.04x | 1.10x | $-10.10 Million |
Industry Comparison
This section compares Mangoceuticals, Inc. Common Stock's net assets metrics with peer companies in the Health Information Services industry.
Industry Context
- Industry: Health Information Services
- Average net assets among peers: $79,108,599
- Average return on equity (ROE) among peers: -247.59%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Mangoceuticals, Inc. Common Stock (MGRX) | $15.73 Million | 0.00% | 0.05x | $3.66 Million |
| Accolade, Inc. (ACCD) | $473.79 Million | -97.02% | 0.91x | $448.32 Million |
| Achiko AG (ACHKF) | $-4.58 Million | 0.00% | 0.00x | $314.42K |
| Ascom Holding AG (ACMLF) | $78.70 Million | 22.11% | 1.51x | $152.13 Million |
| Accelera Innovations Inc (ACNV) | $-462.52K | 0.00% | 0.00x | $5.72K |
| Aclarion Inc (ACON) | $-7.08 Million | 0.00% | 0.00x | $1.89 Million |
| Alternate Health Corp (AHGIF) | $1.07 Million | -2231.82% | 7.94x | $6.50K |
| AI/ML Innovations Inc (AIMLF) | $2.09 Million | -130.52% | 0.72x | $6.84 Million |
| NetraMark Holdings Inc. (AINMF) | $-198.56K | 0.00% | 0.00x | $70.13 Million |
| AMJ Global Technology (AMJT) | $-21.78K | 0.00% | 0.00x | $10.99 Million |
| American Well Corp (AMWL) | $247.79 Million | -38.62% | 0.31x | $78.62 Million |